Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Australian physiotherapy attrition and retention collaboration project: practitioner perspectives.

Physiotherapy theory and practice·2026

Same author

A Hidden Hurdle: The Plastic Surgery Bottleneck in Breast Cancer Care.

The American surgeon·2026

Same author

Characterizing the Clinical Role of Radiation Oncology Advanced Practice Providers Using Entrustable Professional Activities.

Journal of the advanced practitioner in oncology·2026

Same author

Safety and efficacy of conduction system pacing in dual-chamber Pacemakers in a CRT-indicated population: Primary analysis of the CORE-CPP study.

Heart rhythm·2026

Same author

Sports Medicine Physician Burnout-American Medical Society for Sports Medicine Survey Findings.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine·2026

Same author

Back to work: exploring barriers and facilitators to return to work and work participation following traumatic amputation.

Disability and rehabilitation·2026

Search research articles

Related Experiment Video

Updated: Mar 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Adherence to Disease-Modifying Therapies for Multiple Sclerosis.

Lucas Higuera¹, Caroline S Carlin¹, Sarah Anderson²

¹1 Medica Research Institute, Minnetonka, Minnesota.

Journal of Managed Care & Specialty Pharmacy

|November 25, 2016

Summary

Older age, male sex, and lack of depression improve adherence to multiple sclerosis (MS) disease-modifying therapies (DMTs). Oral or infusible DMTs are linked to higher adherence than self-injectable options.

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: Mar 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

Neurology
Pharmacology

Background:

Multiple sclerosis (MS) is a chronic, degenerative neurological disease with no cure.
Disease-modifying therapies (DMTs) are crucial for managing MS symptoms and progression.
Patient adherence to DMTs significantly impacts treatment effectiveness.

Purpose of the Study:

To investigate factors influencing adherence to DMTs in MS patients.
To specifically examine the impact of DMT type on adherence rates.

Main Methods:

Retrospective cohort study using health plan enrollment and claims data (2011-2013).
Included MS patients using a single DMT during the study period.
Adherence defined as medication possession ratio (MPR) of 0.8 or higher.
Multivariate probit models analyzed adherence based on demographics, DMT type, health plan, and health status.

Main Results:

Patients over 45 were 13.7-18.6% more likely to be adherent.
Women had a 5.5% lower adherence probability than men.
Patients using self-injectable DMTs with injection site reactions were 9.1% less likely to be adherent.
Depression diagnosis was associated with a 5.5% lower adherence probability.

Conclusions:

Adherence to MS DMTs varies significantly by patient age, sex, DMT type, and presence of depression.
These factors are critical for optimizing MS management strategies.